Home›Companies›Biotech & Pharma›Illexcor

Illexcor Therapeutics, Inc.

Develops an oral drug for people with sickle cell disease.

Updated Nov 10, 2026·Latest SEC filing May 8, 2026·Suggest an edit

About Illexcor

Illexcor is a private company based in Henrico, Virginia, incorporated in 2026 in Delaware. It has reported $13,000,000 raised in one offering on Form D since May 2026. Its chief executive is Andrew Fleischman.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Apr 15, 2026May 8, 2026$13,000,000of $69.0M target6$2.1MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Illexcor's Form D filed May 8, 2026.

TL
Timothy Ladin
Chief Legal Officer
AF
Andrew Fleischman
CEO and director
Also an executive officer and promoter at Ftv.
TL
Ted Love
Director

Sources

  1. SECIllexcor Therapeutics, Inc. filing history
  2. PressZynext Ventures investment announcement
  3. ResearchHHS recipient information